Paolo Tarantino: ADC stability does not equal ADC tolerability

Paolo Tarantino shared a post by Raffaele Colombo, on X, adding:

”Antibody-drug conjugate (ADC) stability does not equal ADC tolerability.

In medio stat virtus.”

Raffaele Colombo shared a post on X, about recent paper published in npj Precision Oncology:

First-in-human study of DP303c, a HER2-targeted antibody-drug conjugate in patients with HER2 positive solid tumors.

Authors: Jian Zhang, Yiqun Du, Yanchun Meng, Xiaojun Liu, Yuxin Mu, Yunpeng Liu, Yehui Shi, Jufeng Wang, Aimin Zang, Shanzhi Gu, Tianshu Liu, Huan Zhou, Hongqian Guo, Silong Xiang, Xialu Zhang, Suqiong Wu, Huanhuan Qi, Mengke Li and Xichun Hu.

”Trastuzumab envedotin (DP303c): site-specific conjugation, stable linker, drug-to-antibody ratio of 2 with monomethyl auristatin E, 3 milligrams per kilogram.

89 out of 94 patients experienced ocular adverse events.

In contrast…

Trastuzumab vedotin (MRG002): classic conjugation, less stable drug-to-antibody ratio of 4 with monomethyl auristatin E, 2.6 milligrams per kilogram, no ocular toxicity.”

Source: Paolo Tarantino/X and Raffaele Colombo/X

Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan. His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a  publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.

Raffaele Colombo, a  leading figure in the pharmaceutical industry is the Associate Director of Medicinal Chemistry at Zymeworks Inc.. His leadership and scientific acumen drive the discovery and optimization of novel drug candidates and advancing the treatment landscape for various diseases.